Article
Accommodating IOL's new design shows benefits
Results of a multicenter FDA clinical trial of a fourth-generation version of an accommodating IOL (crystalens HD-100, eyeonics/Bausch & Lomb) demonstrate that the lens provides excellent uncorrected visual acuity at all distances that exceeds those of previous versions and without causing loss of contrast sensitivity.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
